PIM
OCUL icon

Provident Investment Management’s Ocular Therapeutix OCUL Stock Holding History

Provident Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,850
Closed -$54K – 58
2022
Q1 		$54K Buy
+10,850
New +$60.1K 0.01% 62

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Provident Investment Management's OCUL Position: Q2 2022 in Review

Provident Investment Management sold out of Ocular Therapeutix (OCUL) in Q2 2022, closing a stake of 10,850 shares — an estimated $54K sold.

Provident Investment Management first reported a position in OCUL in Q1 2022 and held it in 1 quarter. The position peaked at $54K in Q1 2022. 123 funds tracked by Wall St. Rank hold OCUL as of Q2 2022.

  • Provident Investment Management reported no remaining Ocular Therapeutix position as of Q2 2022 after selling out during the quarter.
  • Provident Investment Management sold 10,850 Ocular Therapeutix shares in Q2 2022, an estimated $54K.
  • Provident Investment Management first reported a position in Ocular Therapeutix in Q1 2022 and held it in 1 quarter.
  • Provident Investment Management's Ocular Therapeutix position peaked at $54K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2022.

Based on Provident Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.